No Data
4 Analysts Assess Ocugen: What You Need To Know
4 analysts have expressed a variety of opinions on Ocugen (NASDAQ:OCGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their recent rating
Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study
Ocugen (OCGN) said Wednesday it has completed dosing of the second group of its phase 1/2 clinical study of its experimental gene modifier therapy candidate OCU41OST, being developed as a one-time tre
Express News | HC Wainwright & Co. Reiterates Buy on Ocugen, Maintains $7 Price Target
Ocugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 316.67% HC Wainwright & Co. → $7 Reiterates Buy → Buy 04/22/2024 197.62% Chardan Capital $4 → $
Buy Rating Affirmed for Ocugen on Strong Financials and Advancing Clinical Pipeline
Express News | Ocugen Completed Dosing In The Second Cohort Of Its Phase 1/2 GARDian Clinical Trial For OCU410ST (AAV-HRORA), A Modifier Gene Therapy Candidate For Stargardt Disease As A One-time Treatment